71 Beyond the Surface: Suspicious Nipple Lesions

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 54-55

71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Background/Significance

Nipple lesions, often subtle and easily overlooked, can represent early signs of malignancy, which should prompt pathologic evaluation. These reports highlight the importance of heightened visual interpretation for timely diagnosis and treatment.

Materials and Methods

Cases from a breast surgery tertiary referral hospital illustrate suspicious nipple lesions in 1 male and 4 female individuals.

Results

Case 1: A 46-year-old woman presented with 6 months of painful, spontaneous milky discharge in the left breast with an associated 5-mm yellow nipple scab. Breast mammogram and ultrasound were benign. Shave biopsy revealed breast primary adenocarcinoma. MRI showed diffuse enhancement with nipple-areola complex (NAC) retraction. Lumpectomy confirmed invasive ductal carcinoma (IDC).

Case 2: A 61-year-old woman with persistent right nipple itching, scaling, shape deviation, hyperpigmentation, and a palpable retroareolar mass. Breast imaging showed retroareolar intraductal mass. Final surgical pathology revealed ductal carcinoma in situ (DCIS) and Paget disease.

Case 3: A 70-year-old man with an enlarging verrucous, pruritic left nipple lesion with an associated palpable retroareolar mass. Breast mammogram revealed a 2.6-cm mass, which extended to the nipple, with enlarged ipsilateral axillary lymph nodes. Biopsy confirmed IDC.

Case 4: A 63-year-old woman with right nipple inversion, hyperpigmentation, crusting, and a palpable mass. History of papillary carcinoma resected with clear margins 10 years ago. Ultrasound showed central right breast mass. Ultrasound-guided biopsy revealed atypical ductal hyperplasia. Nipple punch biopsy revealed papillary carcinoma. Mastectomy with sentinel node evaluation confirmed IDC with negative nodes.

Case 5: A 36-year-old woman with a 3-year history of bilateral areolar skin thickening and hyperpigmentation. No scaling, discharge, or pruritus. Bleeding occurred when a lesion was scratched. Breast imaging was benign. Punch biopsy revealed hyperkeratosis of the NAC and possible correlation with T-cell lymphoma.

Conclusion

Meticulous examination of nipple abnormalities is critical in early detection. Clinicians must maintain a high index of suspicion and consider tissue diagnosis for concerning nipple changes.

Articles in this issue

71 Beyond the Surface: Suspicious Nipple Lesions
71 Beyond the Surface: Suspicious Nipple Lesions
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center
75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial
75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial
76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery
76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
Recent Videos
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content